Strs Ohio Ngm Biopharmaceuticals Inc Transaction History

Strs Ohio

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$1.17 - $1.92 $3,393 - $5,568	-2,900 Reduced 5.93%	46,000 $73,000
Q2 2023 Jul 31, 2023	BUY	$2.44 - $4.53 $9,272 - $17,214	3,800 Added 8.43%	48,900 $126,000
Q1 2023 Aug 02, 2023	SELL	$3.72 - $5.4 $14,136 - $20,520	-3,800 Reduced 7.77%	45,100 $184,000
Q3 2022 Oct 27, 2022	SELL	$12.59 - $17.67 $26,439 - $37,107	-2,100 Reduced 4.45%	45,100 $589,000
Q2 2022 Jul 25, 2022	BUY	$10.58 - $17.5 $24,334 - $40,250	2,300 Added 5.12%	47,200 $605,000
Q4 2021 Jan 24, 2022	BUY	$17.26 - $22.02 $203,668 - $259,836	11,800 Added 35.65%	44,900 $795,000
Q3 2021 Oct 22, 2021	SELL	$20.15 - $26.19 $171,275 - $222,615	-8,500 Reduced 20.43%	33,100 $695,000
Q2 2021 Jul 26, 2021	BUY	$15.06 - $30.03 $284,634 - $567,567	18,900 Added 83.26%	41,600 $820,000
Q1 2021 Apr 23, 2021	BUY	$24.99 - $31.93 $184,926 - $236,282	7,400 Added 48.37%	22,700 $659,000
Q2 2020 Jul 23, 2020	BUY	$11.97 - $23.47 $23,940 - $46,940	2,000 Added 15.04%	15,300 $302,000
Q4 2019 Jan 24, 2020	BUY	$9.97 - $20.28 $114,655 - $233,220	11,500 Added 638.89%	13,300 $245,000
Q2 2019 Jul 25, 2019	BUY	$12.56 - $16.6 $22,608 - $29,880	1,800 New	1,800 $26,000

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

Stay updated on Strs Ohio with notifications on news.